---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-25-000109"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:55:19.911781+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcus Bio's EDGE-Gastric Ph2 shows median OS 26.7 months; ORR 59%

## Summary
- Median OS 26.7 months (90% CI: 18.4, NE) for all patients (n=41); PD-L1 high subgroup NE.
- Confirmed ORR 59% (24/41) per RECIST v1.1; 62% in PD-L1 positive and 69% in PD-L1 high subgroups.
- Median PFS 12.9 months overall; 24-month OS rate 50.2% and PFS rate 25.9%.
- Median follow-up 26.4 months; median time on domvanalimab+zimberelimab+chemo was 49 weeks.
- No unexpected safety signals; immune-mediated TEAEs in 22% of patients, infusions reactions in 7%.

## SEC filing metadata
- accession: 0001724521-25-000109
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000109/0001724521-25-000109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000109/rcus-20251012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-25-000109
- JSON: https://secwatch.observer/filing/0001724521-25-000109.json
- Plain text: https://secwatch.observer/filing/0001724521-25-000109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.